How to buy 23andMe Holding stock (23andMe)

Genetic testing company 23andMe is going public via a special purpose acquisition company (SPAC). We'll update this page as new information becomes available.

Our top picks for where to buy 23Andme Holding stock

Buy 23andMe Holding stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

23andMe Holding stock price (NASDAQ: ME)

Use our graph to track the performance of ME stocks over time.

23andMe Holding shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.27
52-week range	$2.66 - $19.34
50-day moving average more info button	$4.27
200-day moving average more info button	$7.52
Wall St. target price	$40.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-122.52

Is it a good time to buy 23andMe Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

23andMe Holding price performance over time

Historical closes compared with the close of $3.06 from 2024-12-19

1 week (2024-12-13)	-8.66%
1 month (2024-11-21)	-5.26%
3 months (2024-09-20)	800.00%
6 months (2024-06-21)	622.55%

1 year (2023-12-21)	259.15%
2 years (2022-12-21)	-93.46%
3 years (2021-12-21)	137.2
5 years (2019-12-17)	N/A

23andMe Holding financials

Revenue TTM	$199.2 million
Gross profit TTM	$132.9 million
Return on assets TTM	-25.77%
Return on equity TTM	-154.21%
Profit margin	0%
Book value	$7.69
Market Capitalization more info button	$82 million

TTM: trailing 12 months

23andMe Holding share dividends

We're not expecting 23andMe Holding to pay a dividend over the next 12 months.

You may also wish to consider:

Have 23andMe Holding's shares ever split?

23andMe Holding's shares were split on a 1:20 basis on 15 October 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 23andMe Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for 23andMe Holding shares which in turn could have impacted 23andMe Holding's share price.

23andMe Holding share price volatility

Over the last 12 months, 23andMe Holding's shares have ranged in value from as little as $2.655 up to $19.344. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 23andMe Holding's is 1.261. This would suggest that 23andMe Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put 23andMe Holding's beta into context you can compare it against those of similar companies.

• Genetic Technologies (GENE.US): 0.48
• Helix Energy Solutions Group (HLX.US): 2.438
• Natera (NTRA.US): 1.529

23andMe Holding overview

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway.

Frequently asked questions

null
What percentage of 23andMe Holding is owned by insiders or institutions?
Currently 3.648% of 23andMe Holding shares are held by insiders and 33.331% by institutions. How many people work for 23andMe Holding?
Latest data suggests 560 work at 23andMe Holding. When does the fiscal year end for 23andMe Holding?
23andMe Holding's fiscal year ends in March. Where is 23andMe Holding based?
23andMe Holding's address is: 349 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 What is 23andMe Holding's ISIN number?
23andMe Holding's international securities identification number is: US90138Q1085